Update on immunotherapy for the treatment of asthma

Current Opinion in Pulmonary Medicine

Volumn 22, Issue 1, 2016, Pages 18-24

  Canonica, Giorgio W ^a   Bagnasco, Diego ^a   Ferrantino, Giovanna ^a   Ferrando, Matteo ^a   Passalacqua, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Allergen immunotherapy; Asthma; Precision medicine; Respiratory allergy; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN;

ALLERGEN IMMUNOTHERAPY; ASTHMA; CLINICAL EFFECTIVENESS; EVIDENCE BASED MEDICINE; HUMAN; IMMUNOTHERAPY; MEDICATION COMPLIANCE; META ANALYSIS (TOPIC); MOLECULAR DIAGNOSIS; PATIENT SAFETY; PERSONALIZED MEDICINE; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; SYSTEMATIC REVIEW (TOPIC); DESENSITIZATION; IMMUNOLOGY; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; HUMANS; PRECISION MEDICINE; SUBLINGUAL IMMUNOTHERAPY;

EID: 84948460796     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0000000000000227     Document Type: Review

References (50)

1. Compalati E, Braido F, Canonica GW. An update on allergen immunotherapy and asthma. Curr Opin Pulm Med 2014; 20:109-117.
2. Canonica GW, Baena-Cagnani CE, Compalati E, et al. 100 years of immunotherapy: the Monaco charter. Under the high patronage of His Serene Highness Prince Albert II of Monaco. Int Arch Allergy Immunol 2013; 160:346-349.
3. Bousquet J, Schünemann HJ, Bousquet PJ, et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIAGA( 2)LEN statement. Allergy 2011; 66:765-774.
4. Zuberbier T, Bachert C, Bousquet PJ, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010; 65:1525-1530.
5. Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J 2014; 7:6.
6. Passalacqua G, Canonica GW. Specific immunotherapy in asthma: efficacy and safety. Clin Exp Allergy 2011; 41:1247-1255.
7. Passalacqua G. Specific immunotherapy in asthma: a synthetic review. J Asthma 2014; 51:29-33.
8. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010; 8:CD001186.
9. Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2013; 124:616-627.
10. Calamita Z, Saconato H, Bronhara Pela A, Atallah AN. Efficacy of sublingual immunotherapy in asthma. Systematic review of randomized clinical trials. Allergy 2006; 61:1162-1172.
11. Penagos M, Passalacqua G, Compalati E, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest 2008; 133:599-609.
12. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-Analysis. Allergy 2009; 64:1570-1579.
13. Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systematic review. JAMA 2013; 309:1278-1288.
14. Bachert C, Canonica GW, Bufe A. SIT: efficacy depends on product, not on route of application. Pediatr Allergy Immunol 2012; 23:401.
15. Thompson CA. Sublingual immunotherapy approved for grass pollen allergies. Am J Health Syst Pharm 2014; 71:770.
16. Bachert C, LarchéM, Bonini S, et al. Allergen immunotherapy on the way to product-based evaluation: a WAO statement. World Allergy Organ J 2015; 8:29.
17. Bonini S. Regulatory aspects of allergen-specific immunotherapy: Europe sets the scene for a global approach. World Allergy Organ J 2012; 5:120-123.
18. Canonica GW, Bachert C, Hellings P, et al. AIT as prototype of precision medicine. World Allergy Organ J 2015 (In press).
19. Braido F, Holgate S, Canonica GW. From blockbusters to biosimilars: an opportunity for patients, medical specialists and healthcare providers. Pulm Pharmacol Ther 2012; 25:483-486.
20. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18:716-725.
21. Holgate ST. Trials and tribulations in identifying new biologic treatments for asthma. Trends Immunol 2012; 33:238-246.
22. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010; 363:301-304.
23. Passalacqua G, Canonica GW. AIT (allergen immunotherapy): a model for the "precision medicine". Clin Mol Allergy 2015; 13:24.
24. Canonica GW, Ansotegui IJ, Pawankar R, et al. A WAO -ARIA -GA2LEN consensus document on molecular-based allergy diagnostics. World Allergy Organ J 2013; 6:17.
25. Passalacqua G, Melioli G, Bonifazi F, et al. The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy 2013; 68:1029-1033.
26. Kaul S, May S, Lüttkopf D, Vieths S. Regulatory environment for allergenspecific immunotherapy. Allergy 2011; 66:753-764.
27. Calderón MA, Casale TB, Togias A, et al. Allergen-specific immunotherapy for respiratory allergies: from meta-Analysis to registration and beyond. J Allergy Clin Immunol 2011; 127:30-38.
28. Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013; 131:1361-1366.
29. Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous Immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy 2010; 40:922-932.
30. Keles S, Karakoc-Aydiner E, Ozen A, et al. A novel approach in allergenspecific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol 2011; 128:808-815.
31. Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014; 69:854-867.
32. Canonica GW, Baena-Cagnani CE, Bousquet J, et al. Recommendations for standardization of clinical trials with allergen-specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007; 62:317-324.
33. Pfaar O, Gerth van Wijk R. Mite-Allergic rhinitis: how to evaluate clinical efficacy in allergen-specific immunotherapy trials? Curr Treat Options Allergy 2015; 2:1-9.
34. Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014; 134:568-575.
35. de Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma: post hoc results froma randomised trial.RespirMed 2014;108:1430-1437.
36. Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol 2015; 114:134-140.
37. Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax 2000; 2:S26-S27.
38. Compalati E, Ridolo E, Passalacqua G, et al. The link between allergic rhinitis and asthma: the united airways disease. ExpertRev Clin Immunol2010; 6:413-423.
39. Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008; 63 (Suppl 86):8-160.
40. Narkus A, Lehnigk U, Haefner D, et al. The placebo effect in allergen-specific immunotherapy trials. Clin Transl Allergy 2013; 3:42.
41. Passalacqua G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006; 61:849-854.
42. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, Year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013; 110:274-353.
43. Cox L, Jacobsen L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol 2009; 103:451-459.
44. Schiappoli M, Ridolo E, Senna G, et al. A prospective Italian survey on the safety of subcutaneous immunotherapy for respiratory allergy. Clin Exp Allergy 2009; 39:1569-1574.
45. Cox LS, Linnemann DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006; 117:1021-1035.
46. Calderón MA, Simons FE, Malling HJ, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012; 67:302-311.
47. Cox L, Larenas Linneman D, Lockey RF, Passalacqua G. Speaking a common language in immunotherapy. WAO grading of systemic reactions. J Allergy Clin Immunol 2010; 125:569-574.
48. Passalacqua G, Baena Cagnani C, Bousquet J, et al. Grading local sideeffects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013; 132:93-98.
49. Cox LS, Hankin C, Lockey R. Allergy immunotherapy adherence and delivery route: location does not matter. J Allergy Clin Immunol Pract 2014; 2:156-160.
50. Passalacqua G, Baiardini I, Senna G, Canonica GW. Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clin Exp Allergy 2013; 43:22-28.